Novartis Drug
- All
- News
- Videos
-
Novartis Pharma Signs World's 1st Licensing Deal For Cancer Drug
Pharmaceutical giant Novartis has signed a licensing agreement increasing access to a vital leukaemia treatment, a UN-backed public health organisation said Thursday, marking the first-ever such agreement for a cancer drug.
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Gujarat Couple Raise Rs 16 Crore For 1 Injection To Save 5-Month-Old Son
A couple from Gujarat has raised Rs 16 crore with the help of a crowdfunding platform to buy a gene therapy injection for the treatment of their 5-month-old son suffering from spinal muscular atrophy, a rare genetic disorder.
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
Just Approved Gene Therapy Drug Is World's Most Expensive At $2.1 Million
The Food and Drug Administration on Friday approved the most expensive drug in the world, a $2.1 million, one-time gene therapy for treatment of a rare disease that afflicts infants.
-
Aurobindo Pharma Buys Parts Of Sandoz US From Novartis For $900 Million
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on higher growth areas. The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance...
-
Swiss Pharmaceutical Giant Novartis To Inject $100 Million Into New Treatments For Malaria
Swiss pharmaceutical giant Novartis on Tuesday announced $100 million of funding over the next five years for research into new treatments for malaria, a mosquito-borne disease with a devastating impact that killed 445,000 people in 2016.
-
India-Origin Vasant Narasimhan Named CEO Of Novartis
Vasant Narasimhan is among a new generation of leaders at Novartis who have sought to improve the process in which drugs move from research to actually becoming a commercial product.
-
Cipla, Wockhardt, Other Drug Makers Pledge To Clean Up Antibiotic Factories
Thirteen leading drug makers promised on Tuesday to clean up pollution from factories making antibiotics and take steps to curb overuse of the medicines as part of a drive to fight the rise of drug-resistant superbugs.
-
European Advisory Panel Recommends Nod For Pfizer Breast Cancer Drug
US drug maker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended.
-
Sun Pharma Inks Distribution Alliance With Mitsubishi Tanabe
Drug major Sun Pharma has announced initiation of a phased transfer of manufacturing and marketing rights of 14 brands, it acquired from Swiss drug firm Novartis in Japan, earlier this year for $293 million.
-
Compound Found To Treat 3 Parasitic Tropical Diseases
In a study published in the journal Nature, scientists at the Genomics Institute of the Novartis Research Foundation found the compound can cure all three diseases in mice, and does not harm normal human cells in laboratory tests.
-
Novartis India Q1 Net Profit At Rs 19 Crore
Drug firm Novartis India reported a standalone net profit of Rs 19.07 crore for the first quarter ended June 30, 2016.
-
Novartis Slumps On Q4 Result Disappointment
Shares of drug firm Novartis India on Friday slumped 13 per cent on disappointment over the company's earnings for the quarter ended March 2016.
-
Novartis Posts Rs 22 Crore Profit In Q4
Drug firm Novartis India on Thursday reported a standalone net profit of Rs 21.53 crore for the quarter ended March 31, 2016.
-
Novartis Pharma Signs World's 1st Licensing Deal For Cancer Drug
Pharmaceutical giant Novartis has signed a licensing agreement increasing access to a vital leukaemia treatment, a UN-backed public health organisation said Thursday, marking the first-ever such agreement for a cancer drug.
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
Gujarat Couple Raise Rs 16 Crore For 1 Injection To Save 5-Month-Old Son
A couple from Gujarat has raised Rs 16 crore with the help of a crowdfunding platform to buy a gene therapy injection for the treatment of their 5-month-old son suffering from spinal muscular atrophy, a rare genetic disorder.
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
Just Approved Gene Therapy Drug Is World's Most Expensive At $2.1 Million
The Food and Drug Administration on Friday approved the most expensive drug in the world, a $2.1 million, one-time gene therapy for treatment of a rare disease that afflicts infants.
-
Aurobindo Pharma Buys Parts Of Sandoz US From Novartis For $900 Million
Novartis AG said on Thursday it would sell the dermatology and generic US oral solids portfolios of Sandoz US to Aurobindo Pharma Ltd for $900 million, as the Swiss drug maker looks to focus on higher growth areas. The deal also includes about 300 products and additional development projects of Sandoz and an additional $100 million in performance...
-
Swiss Pharmaceutical Giant Novartis To Inject $100 Million Into New Treatments For Malaria
Swiss pharmaceutical giant Novartis on Tuesday announced $100 million of funding over the next five years for research into new treatments for malaria, a mosquito-borne disease with a devastating impact that killed 445,000 people in 2016.
-
India-Origin Vasant Narasimhan Named CEO Of Novartis
Vasant Narasimhan is among a new generation of leaders at Novartis who have sought to improve the process in which drugs move from research to actually becoming a commercial product.
-
Cipla, Wockhardt, Other Drug Makers Pledge To Clean Up Antibiotic Factories
Thirteen leading drug makers promised on Tuesday to clean up pollution from factories making antibiotics and take steps to curb overuse of the medicines as part of a drive to fight the rise of drug-resistant superbugs.
-
European Advisory Panel Recommends Nod For Pfizer Breast Cancer Drug
US drug maker Pfizer Inc's breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended.
-
Sun Pharma Inks Distribution Alliance With Mitsubishi Tanabe
Drug major Sun Pharma has announced initiation of a phased transfer of manufacturing and marketing rights of 14 brands, it acquired from Swiss drug firm Novartis in Japan, earlier this year for $293 million.
-
Compound Found To Treat 3 Parasitic Tropical Diseases
In a study published in the journal Nature, scientists at the Genomics Institute of the Novartis Research Foundation found the compound can cure all three diseases in mice, and does not harm normal human cells in laboratory tests.
-
Novartis India Q1 Net Profit At Rs 19 Crore
Drug firm Novartis India reported a standalone net profit of Rs 19.07 crore for the first quarter ended June 30, 2016.
-
Novartis Slumps On Q4 Result Disappointment
Shares of drug firm Novartis India on Friday slumped 13 per cent on disappointment over the company's earnings for the quarter ended March 2016.
-
Novartis Posts Rs 22 Crore Profit In Q4
Drug firm Novartis India on Thursday reported a standalone net profit of Rs 21.53 crore for the quarter ended March 31, 2016.
